Q1 Revenue Upsurge

Nuvation Bio (NUVB) reported first‑quarter revenue that surpassed analyst forecasts by 26%, bolstering its financial profile and supporting a market capitalization of over $2 billion. The oncology pipeline anchors on Ibtrozi, a kinase inhibitor cleared for non‑small‑cell lung cancer, and safusidenib, an IDH1 inhibitor with strong brain‑tumor results. Recent acquisitions include AnHeart Therapeutics, and a non‑dilutive financing structure has preserved shareholder value while expanding the company’s cash runway.